About the Company
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ABBV News
AbbVie: An Undervalued Giant
Gevo (GEVO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, ...
AbbVie to buy Landos Biopharma for $137 million
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie ABBV has outperformed the market over the past 10 years by 2.45% on an annualized basis producing an average annual ...
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
AbbVie has entered into a definitive agreement for the acquisition of Landos Biopharma, in a deal totalling $212.5m.
Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs
Big Pharma’s appetite for safe and effective oral IBD drugs with novel mechanisms of action continues to grow, with my former ...
AbbVie’s New ‘Biological Missile’ Ovarian Cancer Treatment Gets Full FDA Approval
The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen’s cancer drug ...
AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
AbbVie Inc. (ABBV) and Landos Biopharma, Inc. (LABP) announced Monday a definitive agreement under which AbbVie will acquire ...
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage ...
Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc
DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...
AbbVie Secures Full FDA Approval for ADC Elahere in Ovarian Cancer
AbbVie’s antibody-drug conjugate Elahere on Friday won the FDA’s full approval for the treatment of FRα-positive, ...
Loading the latest forecasts...